<DOC>
	<DOC>NCT02326155</DOC>
	<brief_summary>An observational, prospective cohort study to evaluate the safety and efficacy of Remsima™ in patients with Crohn's disease (CD) or Ulcerative Colitis (UC)</brief_summary>
	<brief_title>To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)</brief_title>
	<detailed_description>The primary objective of this study is to assess the safety of Remsima™ by evaluation of Events of Special Interest (ESI) in IBD patients, who have active Crohn's disease (CD), fistulizing Crohn's disease (CD), or Ulcerative Colitis (UC) for up to 5 years for each patient. The secondary objectives of this study are to evaluate additional safety and efficacy of Remsima™ in IBD patients, who have active CD, fistulizing CD or UC. Health-economic parameters will also be assessed</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1. Adult patients with moderate to severe active CD 2. Children and adolescent patients, aged 6 to 17 years old with severe active CD 3. Adult patients with fistulizing active CD 4. Adult patients with moderate to severe active UC 5. Patients (or legal guardian, if applicable) who are willing to give informed consent for long term followup including access to all medical records. 1. Patients with a history of hypersensitivity to infliximab 2. Patients with a current or past history of chronic infection 3. Patients with moderate or severe heart failure (NYHA class III/IV).</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>